New acetylcholinesterase inhibitors

Drugs of the Future

Volumn 22, Issue 4, 1997, Pages 397-410

  Brufani, Mario ^b   Filocamo, Luigi ^b   Lappa, Sperandina ^b   Maggi, Antonio ^a,b  

^a Mediolanum Farmaceutici   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

7 METHOXYTACRINE; 9 AMINO 8 FLUORO 1,2,3,4 TETRAHYDRO 2,4 METHANOACRIDINE; ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMIRIDINE; CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE INHIBITOR; CP 118954; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; HUPERZINE A; PHENSERINE; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG; ZANEPEZIL; ZIFROSILONE;

ALZHEIMER DISEASE; ANOREXIA; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; FATIGUE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; LIVER TOXICITY; NAUSEA; NONHUMAN; REVIEW; VERTIGO; VOMITING;

EID: 0030860195     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. McGeer, P.L., McGeer, E.G. Alzheimer's disease: Arthritis of the brain? Drug News Perspect 1995, 8(2): 80-3.
2. Giacobini, E. Cholinomimetic replacement of cholinergic function in Alzheimer disease. In: Treatment of Dementias: A New Generation of Progress. Advances in Behavioral Biology, Vol. 40. E.M. Meyer, J.W. Simpkins, J. Yamamoto, F.T. Crews (Eds.). Plenum Press: New York 1992, 19-34.
3. Davis, R.E., Doyle, P.D., Carroll, R.T., Emmerling, M.R., Jaen, J. Cholinergic therapies for Alzheimer's disease. Arzneim-Forsch/ Drug Res 1995, 45(1): 425-31.
4. Sussmann, J.L., Harel, M., Frolow, F. et al. Atomic structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein. Science 1991, 253: 872-4.
5. Plgar, L., Hulasz, P. Current problems in mechanistic studies of serine and cysteine proteinases. Biochem J 1982, 207: 1-10.
6. Weise, C., Kreienkamp, H.J., Raba, R., Pedak, A., Aaviksaar, A., Hucho, F. Anionic subsites of the acetylcholinesterase from Torpedo californica: Affinity labelling with the cationic reagent N,N-dimethyl-2-phenyl-aziridium. EMBO J 1990, 9: 3885-8.
7. Raves, M.L., Harel, M., Pang, Y-P., Silman, I., Kozikowski, A.P., Sussman, J.L. Structure of AChE complexed with the nootropic alkaloid, (-) huperzine A. Nat Struct Biol 1997, 4: 57-63.
8. Gentry, M.K., Doctor, B.P. Alignment of amino acid sequences of acetylcholinesterases and butyrylcholinesterases. In: Cholinesterases: Structure, Function, Mechanism, Genetics and Cell Biology. J. Massoulié, F. Bacou, E. Barnard, A. Chatonnet, B. P. Doctor, D. M. Quinn (Eds.). Americam Chemical Society 1991, 394-8.
9. Harel, M., Susmann, J.L., Krejci, E. et al. Conversion of acetylcholinesterase to butyrylcholinesterase: Modeling and mutagenesis. Proc Natl Acad Sci USA 1992, 89: 10827-31.
10. Radic, Z., Reiner, E., Taylor, P. Role of the peripheral anionic site on acetylcholinesterase: Inhibition by substrates and coumarin derivatives. Mol Pharmacol 1991, 39: 98-104.
11. Arendt, T., Bruckner, M.K., Lange, M., Bigi, V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzeimer's disease resemble embryonic development - A study of molecular forms. Neurochem Int 1992, 21: 381-396.
12. Tacrine. Drugs Fut 1987, 12: 1032-5.
13. NIK-247. Drugs Fut 1994, 19: 343-6.
14. SM-10888. Drugs Fut 1991, 16: 33-6.
15. 7-Methoxytacrine. Drugs Fut 1990, 15: 126-9.
16. Sussman, J.L., Harel, L., Silman, I. 3-D Structure of acetylcholinesterase and complexes of it with anticholinesterase agents. In: Membrane Proteins: Structures, Interactions and Models. A. Pullman et al. (Eds.). Kluwer Academic Press: Netherlands 1992, 161-75.
17. Silman, I., Harel, M., Eichler, J., Sussman, J.L., Anselmet, A., Massouliè, J. Structure-function relationships in the binding of reversible inhibitors in the active-site gorge of acetylcholinesterase. In: Alzheimer Disease: Therapeutic Strategies. E. Giacobini, R. Becker (Eds.). Birkhäuser: Boston 1994, 88-92.
18. Brufani, M., Castellano, C., Marta, M., Oliverio, A., Pavone, F., Pomponi, M. Physostigmine derivatives with acetylcholinesterase inhibition properties, and relative production process. US 5306825.
19. Marta, M., Castellano, C., Oliverio, A. et al. New analogs of physostigmine: Alternative drugs for Alzheimers disease? Life Sci 1988, 43: 1921-8.
20. Craig, N.H., Pei, X.F., Soncrant T.T., Ingram D.K., Brossi A. Phenserine and ring C hetero-analogues: Drug candidates for the treatment of Alzheimer's disease. Med Res Rev 1995, 15: 3-31.
21. SDZ-ENA-713. Drugs Fut 1994, 19: 656.
22. Enz, A., Florsheim, P. Cholinesterase inhibitors: An overview of their mechanisms of action. In: Alzheimer Disease: From Molecular Biology to Therapy. E. Giacobini, R. Becker (Eds.). Birkhäuser: Boston 1996, 211-5.
23. TAK-147. Drugs Fut 1995, 20: 248.
24. Villabos, A., Butler, T.N., Chapin, D.S. et al. 5,7-Dihydro-3-[2-[(1 - phenylmethyl) - 4 - piperidinyl] - ethyl] - 6H - pyrrolo -[3,2-f]-1,2-benzisoxazol-6-one: A potent and centrally selective inhibitor of acetylcholinesterase with improved margin of safety. J Med Chem 1995, 38: 2802-8.
25. Panq, Y-P., Kozikowski, A. Prediction of the binding site of 1-benzyl-4-[(5,6-di-methoxy-1-indanon-2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the SYDOC program. J Comput Aided Mol Des 1994, 8: 683-93.
26. Burly, S.K., Petsko, G.A. Aromatic-aromatic interaction: A mechanism of protein structure stabilization. Science 1985, 229: 23-8.
27. Hunter, C.A., Sanders, K.M. The nature of π-π interactions. J Am Chem Soc 1990, 112: 5525-34.
28. Kawakami, Y., Inoue, A., Kawai, T., Wakita, M., Sugimoto, H., Hopfinger, A.J. The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg Med Chem 1996, 9: 1429-46.
29. Cardozo, M.G., Iimura, Y., Sugimoto, H., Yamanishi, Y., Hopfinger, A.J. QSAR analyses of the substituted indanone and benzyl-piperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem 1992, 35: 584-9 (published erratum, J Med Chem 1992, 35: 4767).
30. Cardozo, M.G., Kawai, T., Iimura, Y., Sugimoto, H., Yamanishi, Y., Hopfinger, A. J. Conformational analyses and molecular-shape comparisons of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem 1992, 35: 590-601 (published erratum, J Med Chem 1992, 35: 4768).
31. Bores, G.M., Kosley, R.W. Galanthamine derivatives for the treatment of Alzheimer's disease. Drugs Fut 1996, 21: 621-35.
32. Huperzine A. Drugs Fut 1987, 12: 531-2.
33. Zifrosilone. Drugs Fut 1994, 19: 854.
34. Pang, Y-P., Kozikowski, A. Prediction of the binding site of huperzine A in acetylcholinesterase by docking studies. J Comput Aided Mol Des 1994, 8: 669-81.
35. Holmsted, B., Nordgren, I., Sandoz, M., Sundwall, A. Metrifonate: Summary of toxicological and pharmacological information available. Arch Toxicol 1978, 41: 3-29.
36. Main, A.R. Mode of action of anticholinesterases. Pharmacol Ther 1979, 6: 579-628.
37. Ellman, G.L., Courtney, K.D., Andres, V. Jr., Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7: 88-95.
38. Johnson, C.D., Russell, R.L. A rapid, simple radiometric assay for cholinesterase, suitable for multiple determinations. Anal Biochem 1975, 64: 229-38.
39. Messamore, E., Warpman, U., Ogane, N., Giacobini, E. Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex. Neuropharmacology 1993, 32: 754-60.
40. Cuadra, G., Summers, K., Giacobini, E. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J Pharmacol Exp Ther 1994, 270: 277-84.
41. Mori, F., Lai, C.C., Fusi, F. Giacobini, E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. NeuroReport 1995, 6: 633-6.
42. Hung, A.Y., Haas, C., Nitsch, R.M. et al. Activation of protein kinase C inhibits cellular production of the amyloid β-protein. J Biol Chem 1993, 268: 22959-62.
43. Buxbaum, J.D., Ruefli, A.A., Parker, C.A., Cypress, A.M., Greengard, P. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc Natl Acad Sci USA 1994, 91: 4489-93.
44. Coyle, J.T., Price, D.L., De Lang, M.R. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983, 219: 1184-90.
45. Bartus, R.T., Dean, R.L., Beer, B. Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217: 408-17.
46. Rosem, W.G., Mohs, R.C., Davis, K.I. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984, 141: 1356-64.
47. Mohs, R.C., Davis, B.M., Johns, C.A., Mathe, A.A., Greenwald, B.S., Horvath, T.B. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985, 142: 28-33.
48. Mohs, R.C., Cohen, I. Alzheimer's disease assessment scale (ADAS). Psychopharmacol Bull 1988, 24: 672-8.
49. Eolstein, M.F., Falstein, S.E., McHugh, P.R. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12: 189-98.
50. Jagger, C., Clarke, M., Anderson, J., Battcock, T. Misclassification of dementia by the Mini-Mental State Examination: Are education and social class the only factors? Age Ageing 1992, 21: 404-11.
51. Knapp, M.J., Knopman, D.S., Solomon, P.R. et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994, 271: 985-91.
52. Raisberg, B., Ferris, S.H., De Leon, M.J., Crook, T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982, 139: 1136-9.
53. Kluger, A., Ferris, S.H. Scales for the assessment of Alzheimer's disease. Psychiatr Clin North Am 1991, 14: 309-26.
54. Summers, N.K., Majovski, L.V., Marsh, G.M., Tachiki, K., Kling, A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia. Alzheimer type. New Engl J Med 1986, 315: 1241-5.
55. Davis, K.L., Thal, L.J., Gamzu, E.R. et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. New Engl J Med 1992, 237: 1253-9.
56. Farlow, M., Gracon, S.I., Hershey, L.A., Lewis, K.W., Sadowsky, C.H., Dolan-Ureno, J. A controlled trial of tacrine for Alzheimer's disease. The Tacrine Study Group. JAMA 1992, 327: 2523-9.
57. Watkins, P.B., Zimmerman, H.J., Knapp, M.J., Gracon, S.I., Lewis, K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994, 17: 992-8.
58. Imbimbo, P.B., Lucchelli, P.E. Pharmacodynamic strategy to optimize the clinical response to eptastigmine (MF-201). 3rd Int Springfield Symp Adv Alzheimer Ther (May 11-15, Springfield) 1994, Abst 31.
59. Canal, N., Franceschi, M. Eptastigmine (MF-201). A double-blind placebo-controlled clinical trial in Alzheimer's disease patients. 3rd Int Springfield Symp Adv Alzheimer Ther (May 11-15, Springfield) 1994, Abst 32.
60. Imbimbo, P.B., Lucchelli, P.E. Chronic low dose eptastigmine in Alzheimer patients: Relationship between acetylcholinesterase inhibition and cognitive effects. Neurobiol Aging 1994, 15(Suppl. 1): Abst 410.
61. Imbimbo, B.P., Lucchelli, P.E. Eptastigmine: The cholinergic approach to the treatment of Alzheimer's disease. 2nd Cong Eur Fed Neurol Soc (November 1, Rome) 1996.
62. Rogers, S.L., Friedhoff, L.T. et al. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicenter randomized, double-blind, placebo-controlled trial. Dementia 1996, 7: 293-303.
63. Sandoz's Exelon shows positive results in phase III. Prous Science Daily Essentials. August 9, 1996 (http://www.prous.com/ home_daily).
64. Anand, R., Enz, A. Clinical confirmation of pre-clinical attributes: The ADENA program. 5th Int Conf Alzheimer's Dis Relat Disord (July 24-29, Osaka) 1996, Abst 349.
65. Anand, R., Hartman, R.D., Hayes, P.E., Gharabawi, M. Anoverview of the development of SDZ-ENA-713, a brain selective cholinesterase inhibitor. In: Alzheimer Disease: From Molecular Biology to Therapy. E. Giacobini, R. Becker (Eds.). Birkhäuser: Boston 1996, 239-43.
66. Arnad, R., Gharabaw, G. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: An overview. J Drug Dev Clin Pract 1996, 8: 109-16.
67. Arnad. R., Gharabawi, G. Clinical developpement of Exelon (ENA-713): The ADENA programme. J Drug Dev Clin Pract 1996, 8: 117-22.
68. Mesulam, M.M. Butyrylcholinesterases in Alzheimer's disease. In: Alzheimer Disease: Therapeutic Strategies. E. Giacobini, R. Becker (Eds.). Birkhäuser: Boston 1994, 79-83.
69. Giacobini E., Cuadra G. Second and third generation cholinesterase inhibitors: From preclinical studies to clinical studies to clinical efficacy. In: Alzheimer Disease: Therapeutic Strategies. E. Giacobini, R. Becker (Eds.). Birkhäuser: Boston 1994, 155-71.